GGrantIndex
Sort

326,823 grants matching clinical trial

GVL without GVHD across HLA barriers: Translational Studies

$1,927,639
Megan Sykes · Columbia University Health Sciences · P01 · FY2010 · CA

Pediatric Fungal Network STudy of Rare Invasive Fungal DisEases in Immunocompromised Pediatric Patients (PFN-STRIDE)

$1,927,578
Brian T Fisher · Children'S Hosp Of Philadelphia · U54 · FY2025 · AI

Clinical and Mechanistic Investigations of Salivary Gland Dysfunction

$1,927,479
Blake Warner · National Institute Of Dental & Craniofacial Research · ZIA · FY2025 · DE

Complementing broadly neutralizing antibodies and autologous responses to restrict virus escape and durably suppress HIV-1

$1,927,304
Katharine June Bar · University Of Pennsylvania · U01 · FY2024 · AI

Development of Novel Therapeutic Strategies in Human Leukemias

$1,927,163
Benjamin Levine Ebert · Dana-Farber Cancer Inst · P01 · FY2022 · CA

Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease

$1,927,027
Victor John Thannickal · University Of Alabama At Birmingham · P01 · FY2015 · HL

U OF TEXAS HLTH SCI CTR HOUSTON CENTER FOR CLINICAL AND TRANSLATIONAL SCIENCES

$1,926,846
David D McPherson · University Of Texas Hlth Sci Ctr Houston · UL1 · FY2010 · RR

Growth Factor Imaging and Photoimmunotherapy

$1,926,705
Peter L. Choyke · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA

Clinical and Behavioral Phenotyping of Autism and Related Disorders

$1,926,685
Susan Swedo · National Institute Of Mental Health · ZIA · FY2010 · MH

Emory-MSSM-GSK-NIMH Collaborative Mood and Anxiety Disorders Initiative

$1,926,617
Helen S Mayberg · Emory University · U19 · FY2009 · MH

Refinement and Expansion of the Palliative Care Research Cooperative Group (PCRC)

$1,926,591
Jean S Kutner · Duke University · U24 · FY2016 · NR

Addressing risk through Community Treatment for Infectious disease and Opioid use disorder Now (ACTION) among justice-involved populations

$1,926,146
Sandra Ann Springer · Yale University · U01 · FY2024 · DA

Clinical Trials of Biodefense Vaccines (Dengue)

$1,926,128
Stephen Whitehead · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI

First-In-Human Study of a Humanized Anti-Cocaine Monoclonal Antibody

$1,925,827
Andrew B Norman · University Of Cincinnati · U01 · FY2020 · DA

Development of a recombinant protein vaccine for Chlamydia trachomatis

$1,925,693
Toni Darville · Univ Of North Carolina Chapel Hill · U01 · FY2025 · AI

Systems Pharmacology of Therapeutic and Adverse Responses to ImmuneCheckpoint and Small Molecule Drugs

$1,925,677
Peter Karl Sorger · Harvard Medical School · U54 · FY2022 · CA

A novel therapeutic to ameliorate chronic pain and reduce opiate use

$1,925,647
Boris Tabakoff · Lohocla Research Corporation · UH3 · FY2023 · DA

Community-Based VCT Tanzania

$1,925,570
Michael D Sweat · Medical University Of South Carolina · U01 · FY2009 · MH

Innate Immunity: Elucidation/Modulation - Cancer Therapy

$1,925,557
Ohio State University · P01 · FY2005 · CA

Understanding the molecular mechanisms that contribute to neuropsychiatric symptoms in Alzheimer Disease

$1,925,544
Panagiotis Roussos · Icahn School Of Medicine At Mount Sinai · R01 · FY2019 · AG

Biology and Therapy of High Risk Neuroblastoma

$1,925,523
Robert C Seeger · Children'S Hospital Of Los Angeles · P01 · FY2014 · CA

SWOG Network Group Operations Center of the NCTN

$1,925,494
Charles D. Blanke · Oregon Health & Science University · U10 · FY2023 · CA

DCTD Animal Support

$1,925,432
David Heimbrook · Leidos Biomedical Research, Inc. · N01 · FY2016 · CA

PATHOGENESIS AND TREATMENT OF ACUTE HIV INFECTION

$1,925,423
Bruce D Walker · Massachusetts General Hospital · U01 · FY2006 · AI

Personalized therapeutics for inhibiting breast cancer metastasis

$1,925,413
Debra Auguste · City College Of New York · DP2 · FY2012 · CA